Simon Wabitsch

Simon Wabitsch

Auto-generated profile, based on publicly available information

Simon Wabitsch

Gastrointestinal Malignancy Section, Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2020 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
QZQianfei Zhang
Qianfei Zhang
CMChi Ma
Chi Ma
YDYi Duan
Yi Duan
BHBernd Heinrich
Bernd Heinrich
URUmberto Rosato
Umberto Rosato
TGTim F. Greten
Tim F. Greten
Gut dysbiosis is commonly observed in patients with cirrhosis and chronic gastrointestinal disorders; however, its effect on antitumor immunity in the liver is largely unknown. Here we studied how the gut microbiome affects antitumor immunity in cholangiocarcinoma. Primary sclerosing cholangitis (PSC) or colitis, two known risk factors for cholangiocarcinoma which promote tumor development in mice, caused an accumulation of CXCR2+ polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC). A decrease in gut barrier function observed in mice with PSC and colitis allowed gut-derived bacteria and lipopolysaccharide to appear in the liver and induced CXCL1 expression in hepatocytes through a TLR4-dependent mechanism and an accumulation of CXCR2+ PMN-MDSCs. In contrast, neomycin treatment blocked CXCL1 expression and PMN-MDSC accumulation and inhibited tumor growth even in the absence of liver disease or colitis. Our study demonstrates that the gut microbiome controls hepatocytes to form an immunosuppressive environment by increasing PMN-MDSCs to promote liver cancer.Significance: MDSCs have been shown to be induced by tumors and suppress antitumor immunity. Here we show that the gut microbiome can control accumulation of MDSCs in the liver in the context of a benign liver disease or colitis.See related commentary by Chagani and Kwong, p. 1014.This article is highlighted in the In This Issue feature, p. 995

1 April 2022 in Journal of Hepatology
Verified
Journal Article
Closed access
SWSimon Wabitsch
Simon Wabitsch
JMJustin D. McCallen
Justin D. McCallen
OKOlena Kamenyeva
Olena Kamenyeva
BRBenjamin Ruf
Benjamin Ruf
JMJohn C. McVey
John C. McVey
TGTim F. Greten
Tim F. Greten

30 June 2021 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
BRBenjamin Ruf
Benjamin Ruf
VCVanessa V. Catania
Vanessa V. Catania
SWSimon Wabitsch
Simon Wabitsch
CMChi Ma
Chi Ma
LDLaurence P. Diggs
Laurence P. Diggs
TGTim F. Greten
Tim F. Greten
Mucosal-associated invariant T (MAIT) cells are MR1-restricted innate-like T cells that recognize non-peptide antigens including riboflavin derivates. Although in vitro–activated MAIT cells show antitumor activity, the in vivo role of MAIT cells in cancer is still unclear. Here, we have shown that MAIT cells have antitumor function in vivo when activated by a combination of the synthetic riboflavin synthesis pathway–derived antigen 5-OP-RU [5-(2-oxopropylideneamino)-6-D-ribitylaminouracil] and the Toll-like receptor 9 (TLR9) agonist CpG. Coadministration of 5-OP-RU and CpG induced strong systemic in vivo expansion and activation of MAIT cells with high CD69 expression, pronounced effector memory phenotype, and upregulated levels of effector molecules including IFNγ, granzyme B, and perforin. Activated and expanded MAITs induced a potent and broad antitumor immune response in murine models of liver metastasis and hepatocellular carcinoma, lung metastasis, and subcutaneous tumors in two different mouse strains. Such tumor inhibition was absent in MAIT-deficient Mr1−/− mice. CRISPR/Cas9-mediated MR1 knockout in tumor cells did not affect efficacy of this MAIT-directed immunotherapy, pointing toward an indirect mechanism of action. Our findings suggest that MAIT cells are an attractive target for cancer immunotherapy. See related Spotlight by Lantz, p. 996.

6 September 2018 in Journal of Hepato-Biliary-Pancreatic Sciences
Verified
Journal Article
Closed access
PDF file
FKFelix Krenzien
Felix Krenzien
SWSimon Wabitsch
Simon Wabitsch
PHPhilipp Haber
Philipp Haber
CKCan Kamali
Can Kamali
PBPhilipp Brunnbauer
Philipp Brunnbauer
MSMoritz Schmelzle
Moritz Schmelzle

1 December 2018 in Surgical Oncology
Verified
Journal Article
Closed access
AAAndreas Andreou
Andreas Andreou
BSBenjamin Struecker
Benjamin Struecker
NRNathanael Raschzok
Nathanael Raschzok
FKFelix Krenzien
Felix Krenzien
PHPhilipp Haber
Philipp Haber
JPJohann Pratschke
Johann Pratschke

1 December 2020 in Journal of Laparoendoscopic & Advanced Surgical Techniques
Verified
Journal Article
Closed access
PHPhilipp Konstantin Haber
Philipp Konstantin Haber
SWSimon Wabitsch
Simon Wabitsch
AKAnika Kästner
Anika Kästner
AAAndreas Andreou
Andreas Andreou
FKFelix Krenzien
Felix Krenzien
MSMoritz Schmelzle
Moritz Schmelzle
Background: Despite recent advances in the field of laparoscopic liver surgery, intrahepatic cholangiocarcinoma (iCC) as an entity has been nearly exempted from the new approaches because of proposed technical difficulties in achieving lymphadenectomy (LAD) and beneficial oncologic outcomes. Materials and Methods: Clinical courses of all consecutive patients (n = 159) undergoing liver resection for iCC at the Department of Surgery, Charité—Universitätsmedizin between January 2015 and October 2019 were studied. Ultimately, after applying selection criteria 27 laparoscopic liver resections were compared with 31 open liver resections. Results: Preoperative patient characteristics were similar with regard to general health and tumor characteristics. However, patients in the laparoscopic group tended to have more advanced liver fibrosis. When LAD was performed laparoscopically, a median of eight lymph nodes were resected, complying with current AJCC treatment guidelines. Patients undergoing laparoscopic resection showed lower overall morbidity contributing at least in part to a markedly decreased hospital stay. Conclusions: Herein, we report on one of the largest series of laparoscopically resected iCC, with a high proportion of major resections. Our data show laparoscopic resection to achieve noninferior outcomes to open resection despite impaired preoperative liver function.